IMPACT aims to enhance the therapeutic potential of adipose-derived stromal cell (ASC) by refining the understanding and application of an off-the-shelf, allogeneic ASC product for immunomodulatory clinical use. The objectives include generation of high-quality cell products, developing assays to explore and predict the therapeutic potential of ASC, and uncovering the full potential of cell therapy through manufacturing, clinical testing, and innovation. The project involves a multicenter clinical trial, personalized medicine, innovation, and utilizes state-of-the-art production technology. The project addresses knowledge gaps in quantifying differences in ASC functionalities and relationship to clinical effects, an essential prerequisite for progression of ASC-based cell therapy to pivotal trial and commercialization. It focuses on the potential of ASC for treating non-ischemic heart failure and explores advancements in administration. Comprehensive data integration provides understanding of the interplay between cell product and patient, potentially leading to novel identification of mechanisms of action, tailored cell therapies, innovation, and recommendations for future directions. IMPACT will facilitate translation of research into clinical practice. A team of experts with extensive experience in producing therapeutic cell products and conducting clinical trials, will ensure scientific integrity, and the prospect of making an IMPACT by advancing ASC therapy.

The project aims to address the significant challenges of infertility, particularly focusing on male and female infertility and the related conditions of premature ovarian failure and polycystic ovarian syndrome. The project is a collaboration between Herlev Hospital and XY Therapeutics, a company that target the RANKL signaling pathway, which shows promising potential for improving fertility outcomes. The project also includes Center for Diagnostics who will assist with the development of a companions diagnostic tool. The project builds on an already strong foundation, but will strengthen the scientific and commercial aspects of the technology significantly, by expanding the indication of RANKL inhibition for to men with severely impaired sperm production or no semen production, developing a companion diagnostic tool, and investigating the impact of RANKL modulation on female reproductive function. The project encompasses a mixture of smaller investigative clinical trials and exploratory development activities within infertility. Overall, the project holds potential to make a significant economic and societal impact by providing breakthrough solutions to individuals and couples facing the burden of infertility.